Dr. Michael Daniel Mancenido, DO

Dr. Mancenido practices at Unity Hospital - Unit in Rochester, New York.

Dr. Mancenido's NPI, 1669536496, was assigned on December 19, 2006. Dr. Mancenido graduated from University of New England College of Osteopathic Medicine in 2001. Dr. Mancenido holds New York license 242401.

Dr. Mancenido's primary practice is Unity Hospital - Unit, at 1555 Long Pond Rd, Rochester, NY 14626 in Monroe County. The practice phone is (585) 368-3002.

Dr. Mancenido's primary practice is Unity Hospital - Unit in Rochester, New York. Dr. Mancenido is also affiliated with Rochester General Hospital. The medical group on file is Unity Physician Services. Dmand AI also links Dr. Mancenido to 2 more hospitals, 2 medical groups, 1 group practice or clinic and 1 home health agency, each named with a free account. Dr. Mancenido's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mancenido practices, 6 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Mancenido's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Mancenido is licensed in New York.

CMS data shows 250 Medicare services from Dr. Mancenido across 5 procedure codes in 2024, for 128 Medicare patients. Medicare paid $19,947 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Dr. Mancenido in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 3.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mancenido's median patient age at 70, with 40% women.

In 2024, Dr. Mancenido wrote 603 Medicare Part D claims for 105 patients. 79% of them were for generic drugs. CMS names the drug for 428 of them, across 23 drugs with 11 or more claims each, at $139,812 in total drug cost. In 2023, CMS named 158 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Mancenido for performance year 2024, reported through an alternative payment model (APM). Dr. Mancenido accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mancenido as offering telehealth.

Dmand AI links 1 paper to Dr. Mancenido in 2024. Dr. Mancenido's most frequent co-authors are Roberto B. Corales, DO, Jacob Scutaru, MD and William M. Valenti, MD.

CMS Open Payments shows 188 general payments to Dr. Mancenido from 12 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. ViiV Healthcare Company paid the most, $26,382.

Dr. Mancenido graduated from University of New England College of Osteopathic Medicine in 2001.